A 48-year-old woman admitted to the ICU with ventilator-associated pneumonia (VAP) has a tracheal aspirate culture positive for Klebsiella pneumoniae. Antibiotic susceptibility testing shows resistance to imipenem and meropenem, but susceptibility to colistin and tigecycline. The organism produces a metallo-β-lactamase (MBL) on molecular testing. She is currently on day 2 of empiric meropenem monotherapy. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This is a case of **ventilator-associated pneumonia (VAP)** caused by a **carbapenem-resistant K. pneumoniae (CRKP)** producing a **metallo-β-lactamase (MBL)**. ### Microbiological Basis **Key Point:** Metallo-β-lactamases (MBLs, e.g., NDM-1, IMP, VIM) are zinc-dependent enzymes that hydrolyze ALL β-lactams, including carbapenems. They are NOT inhibited by standard β-lactamase inhibitors (clavulanic acid, sulbactam). **High-Yield:** MBL-producing organisms = **carbapenem-resistant** = treatment failure with carbapenems. This is a critical distinction from ESBL-producers (which remain carbapenem-susceptible). ### Resistance Mechanism Comparison | Feature | ESBL | MBL (Carbapenem-Resistant) | |---------|------|----------------------------| | **Substrate** | 3rd-gen cephalosporins, penicillins | ALL β-lactams (including carbapenems) | | **Inhibitor** | Clavulanic acid, sulbactam | NOT inhibited by standard inhibitors | | **Carbapenem susceptibility** | Susceptible ✓ | Resistant ✗ | | **Mechanism** | Serine β-lactamase | Zinc-dependent metallo-enzyme | | **Treatment** | Carbapenem (imipenem/meropenem) | Colistin, tigecycline, aztreonam | ### Management Algorithm ```mermaid flowchart TD A[Gram-negative infection<br/>on carbapenem therapy]:::outcome --> B{Clinical improvement?}:::decision B -->|Yes| C[Continue carbapenem]:::action B -->|No| D{Check susceptibilities}:::decision D -->|Carbapenem-susceptible| E[Optimize carbapenem dosing]:::action D -->|Carbapenem-resistant| F{MBL or OXA?}:::decision F -->|MBL detected| G[Switch to colistin<br/>or tigecycline]:::action F -->|OXA-type| H[Consider aztreonam<br/>+ β-lactamase inhibitor]:::action G --> I[ID consultation<br/>recommended]:::action H --> I ``` ### Why Switch Immediately? 1. **Meropenem is ineffective** — MBLs hydrolyze the carbapenem β-lactam ring; continuing it will result in clinical failure and worsening VAP. 2. **Colistin and tigecycline are the agents of choice** for MBL-producing organisms in serious infections like VAP. 3. **Infectious disease consultation** is strongly recommended for optimal dosing, monitoring, and outcome in this complex, high-mortality scenario. 4. **No time for repeat culture** — the organism is identified, MBL is confirmed, and susceptibilities are known. **Clinical Pearl:** Carbapenem resistance in gram-negatives is a red flag for MBL or OXA-type carbapenemase. Do NOT continue carbapenem therapy; switch immediately to colistin or tigecycline. **Mnemonic: MBL-FAIL** — Metallo-β-Lactamase = Failure with carbapenems; switch to colistin/tigecycline. **Warning:** ~~Aminoglycosides alone are NOT effective~~ against MBL-producers; they must be combined with a β-lactam (e.g., aztreonam) or used as adjunctive therapy only. [cite:Harrison 21e Ch 297; Robbins 10e Ch 8]